Combined Radionuclide Therapy and Immunotherapy for Treatment of Triple Negative Breast Cancer

Triple negative breast cancer (TNBC) is an aggressive subtype of the disease with poor clinical outcomes and limited therapeutic options. Immune checkpoint blockade (CP) has surged to the forefront of cancer therapies with widespread clinical success in a variety of cancer types. However, the percen...

Descripción completa

Detalles Bibliográficos
Autores principales: Vito, Alyssa, Rathmann, Stephanie, Mercanti, Natalie, El-Sayes, Nader, Mossman, Karen, Valliant, John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8124136/
https://www.ncbi.nlm.nih.gov/pubmed/34063642
http://dx.doi.org/10.3390/ijms22094843

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8124136/
https://www.ncbi.nlm.nih.gov/pubmed/34063642
http://dx.doi.org/10.3390/ijms22094843

Ejemplares similares